Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Asset Resilience Ratio
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has an Asset Resilience Ratio of -0.13% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002864 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Asset Resilience Ratio has changed over time. See Shaanxi Panlong Pharmaceutical Group Lim balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shaanxi Panlong Pharmaceutical Group Lim worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-2.77 Million | -0.13% |
| Total Liquid Assets | CN¥-2.77 Million | -0.13% |
Asset Resilience Insights
- Limited Liquidity: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A maintains only -0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.13% | CN¥-2.87 Million ≈ $-419.60K |
CN¥2.13 Billion ≈ $310.96 Million |
+0.47pp |
| 2022-12-31 | -0.61% | CN¥-11.77 Million ≈ $-1.72 Million |
CN¥1.93 Billion ≈ $282.53 Million |
-0.72pp |
| 2021-12-31 | 0.11% | CN¥1.48 Million ≈ $217.12K |
CN¥1.33 Billion ≈ $194.65 Million |
-5.29pp |
| 2019-12-31 | 5.41% | CN¥50.21 Million ≈ $7.35 Million |
CN¥928.88 Million ≈ $135.92 Million |
-- |
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more